NCT00368927View on ClinicalTrials.gov

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

December 31, 2010

Conditions
Precancerous ConditionStage I Non-small Cell Lung CancerTobacco Use Disorder
Interventions
DRUG

sulindac

Given orally

OTHER

placebo

Given orally

Trial Locations (6)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

01805

Lahey Hospital and Medical Center, Burlington

V5Z 1L3

British Columbia, Vancouver

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00368927 - Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia | Biotech Hunter | Biotech Hunter